BioNTech is a German biotechnology company known primarily for its development of innovative therapies and vaccines, particularly in the field of immunotherapy for cancer and infectious diseases. Founded in 2008, BioNTech gained significant global attention during the COVID-19 pandemic for its development of a messenger RNA (mRNA) vaccine in partnership with Pfizer. This vaccine was one of the first to be authorized for emergency use against COVID-19, demonstrating the potential of mRNA technology in rapid vaccine development. BioNTech’s work extends beyond vaccines, as the company is also engaged in creating personalized cancer therapies and treatments for various diseases, utilizing its proprietary mRNA technology and other platforms to harness the human immune system’s potential.
BioNTech is transitioning from pandemic defense to a focus on cancer treatment using mRNA technology. 2024 financial results show a profit decline to €1.08 per share, a reduction from €1.90,…